Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease

Clinical Chemistry

Volumn 48, Issue 8, 2002, Pages 1265-1271

  Ylikoski, Alice ^a   Pettersson, Kim ^a   Nurmi, Jussi ^a   Irjala, Kerttu ^a   Karp, Matti ^a   Lilja, Hans ^a   Lövgren, Timo ^a   Nurmi, Martti ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN 2; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; SOLID TUMOR;

EID: 0036320575     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.8.1265     Document Type: Article

References (47)

1. High level of expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen
2. Expression of the gene coding for human prostate-specific antigen and related hGK-1 in benign and malignant tumors of the human prostate
3. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein
4. Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma
5. Three predominant proteins secreted by the human prostate gland
6. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids
7. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium
8. Kallikrein gene expression in human pituitary tissues
9. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions
10. Human glandular kallikrein in breast milk, amniotic fluid, and breast cyst fluid
11. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2
12. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2
13. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer
14. 1-antichymotrypsin
15. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening
16. Prostate-specific antigen: Its usefulness in clinical medicine
17. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum
18. Human glandular kallikrein 2: A potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer
19. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL
20. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma
21. Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2
22. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
23. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages
24. A sensitive method for a detection of a prostate tumor cell marker using the polymerase chain reaction
25. Detection of hematogenous micrometastasis in patients with prostate cancer
26. Detection of prostate-specific antigen mRNA by reverse transcription polymerase chain reaction and time-resolved fluorometry
27. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay
28. Improved reverse transcriptase polymerase chain reaction protocol with exogenous internal competitive control for prostate-specific antigen mRNA in blood and bone marrow
29. Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer
30. Detection of prostate cancer cells circulating in peripheral blood by reverse transcription-PCR for hKLK2
31. Molecular staging of prostate cancer. II. A comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen
32. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: Comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays
33. Sensitive detection of prostatic hematogenous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction
34. The expression of prostate-specific membrane antigen in peripheral blood leukocytes
35. Detection of prostatic cells in peripheral blood: Correlation with serum concentrations of prostate-specific antigen
36. Enhanced reverse transcriptase polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer
37. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy
38. Quantitative polymerase chain reaction does not improve preoperative prostate cancer staging: A clinicopathological molecular analysis of 121 patients
39. Basal PSA mRNA levels detected by quantitative reverse transcriptase polymerase chain reaction (Q-RT-PCR-PSA) in blood from subjects without prostate cancer
40. Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: Implications for the detection of hematogenous prostate cells and standardization
41. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: Implications for detection of micrometastases
42. Dual-label detection of amplified products in quantitative RT-PCR assay using lanthanide-labeled probes
43. Quantitative reverse transcription-PCR assay with an internal standard for the detection of prostate-specific antigen mRNA
44. Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients
45. Serum free prostate specific antigen and prostate specific antigen density measurements for predicting cancer in men with prior negative prostatic biopsies
46. 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer
47. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas